Heterocyclic Compounds Targeting HBV cccDNA for Viral Cure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections are limited, as existing medications only suppress virus replication without curing the infection, and there is no cure or vaccine available for HDV, leading to severe complications and high fatality rates, especially when combined with HBV.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, which is used in pharmaceutical compositions to inhibit HBV and HDV replication by administering an effective amount to infected subjects, targeting the covalently closed circular DNA form of HBV to prevent viral reemergence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat HBV and HDV infections, then virus replication is suppressed, but the infection is not cured and viral reemergence occurs
Solution Approach 1:
The compound is designed to target and eliminate the covalently closed circular DNA (cccDNA) reservoir before viral reemergence can occur. By preliminarily destroying the persistent viral template, the treatment achieves curative potential rather than merely suppressing replication temporarily, thereby extending the duration of viral freedom.
Solution Approach 2:
The invention extracts and eliminates the root cause of viral persistence—the cccDNA reservoir—separating it from the active viral replication cycle. By specifically targeting this hidden reservoir and removing it, the treatment addresses the fundamental limitation of existing therapies that only suppress active replication without eliminating the persistent template.
2Object-affected harmful factors
If existing medications suppress HBV and HDV replication, then viral load is reduced, but no cure is available and severe complications occur
Solution Approach 1:
The compound converts the previously harmful cccDNA reservoir, which causes persistent infection and complications, into a therapeutic target. By designing the treatment to specifically eliminate this persistent viral template, the invention transforms the source of chronic infection into the key to achieving a cure, thereby preventing severe liver complications and reducing fatality rates.
Solution Approach 2:
The treatment preliminarily eliminates the cccDNA reservoir before it can generate harmful viral reemergence and subsequent liver complications. By taking this preventive action against the persistent viral template, the invention stops the progression to severe complications and fatalities that occur with existing suppressive therapies.
3Adaptability or versatility
If existing treatments are used for HDV infection, then no specific therapy is available, but fatality rate remains high
Solution Approach 1:
The compound is designed with universal activity against both HBV and HDV infections by targeting the conserved cccDNA reservoir mechanism common to both viruses. This multi-functional approach provides much-needed treatment options for HDV, which previously had no specific therapy, while maintaining effectiveness against HBV, thereby reducing fatality rates across both infections.
Solution Approach 2:
The invention converts the lack of HDV-specific treatment into an opportunity by designing a compound that targets the fundamental cccDNA persistence mechanism shared by both HBV and HDV. This approach transforms the unmet medical need into a therapeutic solution, providing the first specific treatment for HDV and significantly reducing fatality rates.
Data Source
AI summary
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.